Search results
Showing 796 to 810 of 1329 results for nice quality standards or clinical guidelines
iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia (MIB306)
NICE has developed a medtech innovation briefing (MIB) on iTind for lower urinary tract symptoms caused by benign prostatic hyperplasia .
Idelalisib for treating refractory follicular lymphoma (TA604)
Evidence-based recommendations on idelalisib (Zydelig) for follicular lymphoma that has not responded to 2 prior lines of treatment in adults.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Find out more about the types of organisations that can register to be a stakeholder at NICE.
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanoma (TA837)
Evidence-based recommendations on pembrolizumab (Keytruda) for the adjuvant treatment of resected stage 2B and 2C melanoma in people 12 years and over.
NICE has developed a medtech innovation briefing (MIB) on Optilume for anterior urethral strictures .
NICE has developed a medtech innovation briefing (MIB) on 24/7 EEG SubQ for epilepsy .
Evidence-based recommendations on continuous positive airway pressure for treating obstructive sleep apnoea/hypopnoea syndrome in adults.
This indicator covers the percentage of patients with moderate or severe frailty and/or multimorbidity who have received a medication review in the last 12 months which is structured, has considered the use of a recognised tool and taken place as a shared discussion. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM186
Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry (MIB113)
NICE has developed a medtech innovation briefing (MIB) on the Nasal Alar SpO2 sensor for monitoring oxygen saturation by pulse oximetry .
This guideline covers good practice for managing medicines in care homes. It aims to promote the safe and effective use of medicines in care homes by advising on processes for prescribing, handling and administering medicines. It also recommends how care and services relating to medicines should be provided to people living in care homes.
icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)
NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .
Esketamine nasal spray for treatment-resistant depression (TA854)
Evidence-based recommendations on esketamine (Spravato) for treatment-resistant depression in adults.
Evidence-based recommendations on apixaban (Eliquis) for treating and preventing recurrent deep vein thrombosis or pulmonary embolism in adults.
UroShield for preventing catheter-associated urinary tract infections (HTG620)
Evidence-based recommendations on UroShield for preventing catheter-associated urinary tract infections.